Nivolumab improves health-related quality of life (HRQoL) of patients with advanced melanoma, in contrast to dacarbazine, according to a study published in the Annals of Oncology.1
The authors evaluated the HRQoL of patients enrolled to CheckMate 066, a phase 3 study that contrasted the efficacy of nivolumab with that of dacarbazine, for patients with untreated, unresectable, or metastatic melanoma.
Throughout study treatment, 65% of patients receiving dacarbazine and 70% of patients receiving nivolumab completed quality of life questionnaires. Baseline HRQoL scores were similar, though at several points after baseline, there was a meaningful difference in favor of nivolumab.
HRQoL of patients in the nivolumab group deteriorated later than HRQoL of those who received dacarbazine.
The authors concluded that HRQoL of patients with advanced melanoma is superior when nivolumab, rather than dacarbazine, is administered.
HRQoL was measured using the European Organisation for Research and Treatment of Care (EORTC) Core Quality of Life Questionnaire (QLQ-C30), as well as the EuroQoL 5 Dimensions Questionnaire (EQ-5D).
- Long GV, Atkinson V, Ascierto PA, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase 3 checkmate 066 study. Ann Oncol. 12 Jul 2016. doi: 10.1093/annonc/mdw265 [Epub ahead of print]